AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01900938 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous infusion of propofol
Description: Propofol is continuously administered intravenously via infusion pump starting with 20 mg/kg/hr and then titrated to about 5 mg/kg/hr according to patients' sedation level.
Study NCT01900938 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent bolus injection of propofol
Description: A loading dose of 2 mg of midazolam and 0.4 mg/kg of propofol is initially injected and then repeated intermittent bolus injection of 20 mg of propofol is followed according to patients' sedation level.
Study NCT01900938 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Study NCT01900938 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Study NCT00617578 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ATP One Shot ON
Description: The new antitachycardia pacing algorithm ATP One Shot attempts to terminate fast VT by one ATP sequence and thus avoid defibrillation shock delivery
Study NCT00617578 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ATP One Shot OFF
Description: Standard defibrillation shock delivery
Study NCT02443948 — intervention group
Intervention type: OTHER
Intervention: Vena puncture for blood collection
Description: Cf-DNA blood samples will be collected in EDTA tubes (20 ml) during the routine blood test
Study NCT01559844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: Sofosbuvir 400 mg (2 x 200 mg tablets) administered orally once daily
Study NCT01559844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
Study NCT05151302 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: computer vision symptom scale (CVSS) questionnaire
Description: Subjects working at VDT for >20 hours a week and accessing to the Eye Clinic in order to complete an ocular examination and subjects working at the Foundation accessing to the Eye Clinic in order to complete an ocular status evaluation according to Italian Law 81/08 will be asked to self-complete the questionnaire in presence of the attending junior ophthalmologists prior to the visit with the Ophthalmologist, to avoid interference with visit results (communication of bad/good news)
Study NCT01764165 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen
Description: oxygen at a rate of 2 L/min will be delivered through a small nasal cannula throughout sleep.
Study NCT01764165 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High flow of room air
Description: Warm and humidified air at rates of 20 L/min will be delivered through a small nasal cannula throughout sleep
Study NCT02181803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8189
Description: MK-8189, oral, 2 mg and/or 10 mg tablets, taken QD for a total daily dose of 2 mg, 4 mg, 8 mg, 10 mg, 12 mg, 14 mg, 16 mg, 20 mg, or 40 mg
Study NCT00729508 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cat-PAD
Description: Cat-PAD dose 1X 4 administrations 2 weeks apart
Study NCT00729508 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cat-PAD
Description: Cat-PAD dose 1X 4 administrations 4 weeks apart
Study NCT00729508 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cat-PAD
Description: Cat-PAD dose 1X 8 administrations 2 weeks apart
Study NCT00729508 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Cat-PAD
Description: Placebo
Study NCT02181803 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching oral 2 mg and/or 10 mg MK-8189 tablets, taken QD
Study NCT02181803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Base Monotherapy
Description: For Part 2 only: participants need to be on monotherapy with an atypical antipsychotic medication (eg, Olanzapine, Quetiapine, Paliperidone, Asenapine, Iloperidone, Aripirprazole, Lurasidone, Risperidone \[not to exceed daily dose of 6 mg\], or Ziprasidone.) The participant should be on a stable and well tolerated treatment regimen for at least 2 months prior to screening. NOTE: Clozapine is not allowed.
Study NCT02181803 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Base Monotherapy
Description: For Part 2 only: participants need to be on monotherapy with an atypical antipsychotic medication (eg, Olanzapine, Quetiapine, Paliperidone, Asenapine, Iloperidone, Aripirprazole, Lurasidone, Risperidone \[not to exceed daily dose of 6 mg\], or Ziprasidone.) The participant should be on a stable and well tolerated treatment regimen for at least 2 months prior to screening. NOTE: Clozapine is not allowed.
Study NCT04203693 — intervention group
Intervention type: DRUG
Intervention: Tildrakizumab
Description: The study physicians will choose the treatment independently of the enrolment in the study according to routine care.
Study NCT01248832 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Counseling
Description: Counseling is conducted in Mandarin, Cantonese, Korean, or Vietnamese by counselors at the Helpline. The protocol used is similar to that proved efficacious. However, to make the counseling culturally appropriate for Asian language speakers, we: capitalizing on first contact, present the Helpline as a credible quit smoking program staffed by experts, avoid the term counseling since it is associated with mental illness, and assume a more authoritative role and directive counseling style. Counseling is proactive (1st call is made by smoker, then subsequent calls are made by the counselor) to help reduce attrition. Counseling includes a 30-40 minute comprehensive pre-quit session plus up to 5 shorter follow-up calls (about 10 minutes) scheduled according to the probability of relapse.
Study NCT01248832 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-Help Materials
Description: All subjects (both in the telephone counseling group and the materials-only group) receive self-help materials in teh appropriate language. Materials were created in-house, are written in the appropriate language, and cover the essentials of the quitting process such as motivation, physiological and emotional responses to quitting, nicotine in the body, quitting aids, quitting strategies (including those that might be culturally specific such as acupuncture or herbs), setting a quit date, planning, relapse prevention, differentiating between slips and relapse, long-term maintenance, and developing the nonsmoker self-image.
Study NCT01248832 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Help Materials
Description: All subjects (both in the telephone counseling group and the materials-only group) receive self-help materials in teh appropriate language. Materials were created in-house, are written in the appropriate language, and cover the essentials of the quitting process such as motivation, physiological and emotional responses to quitting, nicotine in the body, quitting aids, quitting strategies (including those that might be culturally specific such as acupuncture or herbs), setting a quit date, planning, relapse prevention, differentiating between slips and relapse, long-term maintenance, and developing the nonsmoker self-image.
Study NCT00951041 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK investigational vaccine GSK2340272A
Description: Two intramuscular injections
Study NCT00951041 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK investigational vaccine GSK2340269A
Description: Two intramuscular injections
Study NCT03687190 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai chi
Description: participants were required to receive hospital-based Tai chi training at least once a month, and home-based Tai chi exercise at least three times a week over the next 9 months
Study NCT03687190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: conventional medicine
Description: participants without Tai chi training still received routine conventional medicine
Study NCT03687190 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: conventional medicine
Description: participants without Tai chi training still received routine conventional medicine
Study NCT02881723 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Study NCT02881723 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radio- chemotherapy
Study NCT02401568 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Dynamic CT
Description: Various low dose CT acquisitions will be successively performed on the wrist to allow a four dimensional evaluation. The same type of acquisition will be performed during various manoeuvers (radio-ulnar deviation, clenching fist, and dart-throwing motion).
Study NCT02401568 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Arthrography
Description: percutaneous intra-articular injection of contrast media in the medio-carpal and radio-carpal joints
Study NCT02035800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Patient will received medication as standard of care
Study NCT02131272 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin detemir
Description: Administered subcutaneously (s.c., under the skin) once or twice daily. The subjects' pre-trial OAD's i.e. metformin treatment should continue unchanged during the treatment period.
Study NCT02131272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin NPH
Description: Administered subcutaneously (s.c., under the skin) once or twice daily. The subjects' pre-trial OADs i.e. metformin treatment should continue unchanged during the treatment period.
Study NCT02131272 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet/exercise
Description: Intervention will be performed through family based changes in eating and activity behaviours.
Study NCT02131272 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet/exercise
Description: Intervention will be performed through family based changes in eating and activity behaviours.
Study NCT04474626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoquercetin
Description: Oral, 1 time per day, per predetermined dosed per 28 treatment cycle.
Study NCT01088139 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein supplementation
Description: Ready made protein supplement drinks with approximate protein content of 18-24g per 500ml per day. Caloric content is 490 to 530Kcal depending on the brand of drink.
Study NCT01922115 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trospium Chloride
Description: Subject will be administered either placebo or 60 mg dosage of Sanctura XR for treatment of overactive bladder. Subject will take Sanctura XR once every morning. Blood will be drawn for plasma extraction at each visit.
Study NCT01922115 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03280758 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Muscle Strengthening exercises
Description: Participants will be required to participate in resistance training 3 hours per week.
Study NCT03188848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPI-3016
Description: Single-dose subcutaneous injection of BPI-3016
Study NCT03188848 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single-dose subcutaneous injection of placebo to match BPI-3016
Study NCT03319940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tarlatamab
Description: Tarlatamab is a Half-Life Extended (HLE) Bispecific T cell engager (BiTE®) targeting delta-like protein 3 (DLL3)
Study NCT03319940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is a potent humanized IgG4 monoclonal antibody (mAb) with high specificity of binding to the PD-1 receptor, thus inhibiting its interaction with PD-L1 and PD-L2
Study NCT03319940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRS Mitigation Strategies
Description: Participants will be treated with one of the CRS mitigation strategies.
Study NCT01795833 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Short text messages
Description: In addition to structured education on healthy lifestyle provided at baseline, subjects in the arm will receive short text messages containing educational, motivational and supportive content on diet, physical activity, and smoking (if appropriate) during the study period. The content will be appropriate to the stage of the transtheoretical model of behavioural change that the subject is in. This will be assessed by questionnaire at each visit to clinic.
Study NCT00381940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Description: Given IV
Study NCT00381940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV
Study NCT00381940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine tartrate
Description: Given IV
Study NCT00381940 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given IV or SC
Study NCT00798720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: 400 mg by mouth once daily for days 1-14 of each 21 day cycle
Study NCT00798720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: 1.3 mg/m2 IV on days 1, 4, 8, 11 of each 21 day cycle
Study NCT03154801 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Paramedical care
Description: Paramedical early detection of sexual dysfunction and sexual health counseling
Study NCT03211260 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EQUISTASI
Description: Equistasi is a nanotechnology for proprioceptive focal stimulation. Every patient will receive four patches to be placed on both legs for 4 weeks.
Study NCT00081224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Study NCT02863068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Sodium Nitrite
Description: Subjects will have 0.1 cm of 2% sodium nitrite cream applied per 1 cm2 of the total ulcerated area. Areas will be rounded to the nearest 1 cm2. If a subject has more than one ulcer, all of them will be treated with either study cream in this intervention.
Study NCT02863068 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will have Placebo applied to total ulcerated area. If a subject has more than one ulcer, all of them will be treated with placebo in this intervention.
Study NCT00986206 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Biomarker LPA and HE4
Description: Non Interventional Trial
Study NCT02934490 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mesh
Description: Meshes were made by Gynemech TM PS, (Johnson \& Johnson Shanghai Medical Equipment Co. SFDA registration No. 3460365, size 10 × 15cm)
Study NCT00081224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib
Study NCT03322969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel/DDP
Description: receiving the modified chemotherapy
Study NCT03322969 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: XELOX/SOX
Description: receiving the original chemotherapy
Study NCT03663868 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CC-Test
Description: Classification of the oocyte/embryo based on the gene expression pattern observed in the cumulus cells
Study NCT00668954 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Pomegranate Juice
Description: Group A drinks 8 oz. pomegranate juice/day for 12 weeks
Study NCT00668954 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Juice
Description: Group B drinks 8 oz. placebo juice/day for 12 weeks
Study NCT03561090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IW-3718
Description: oral tablet
Study NCT03561090 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral tablet
Study NCT03561090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard-dose PPIs QD
Description: background therapy
Study NCT03561090 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard-dose PPIs QD
Description: background therapy
Study NCT04150679 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: duodenojejunostomy access loop
Description: ROUX en Y hepaticojejunostomy with duodenojejunal anastomosis as permanent access
Study NCT04150679 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: hepaticojejunostomy without access loop
Description: ROUX en Y hepaticojejunostomy without access loop
Study NCT03362567 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sustained Natural Apophyseal Glides
Description: Subjects in SNAGS group were treated with sustained natural apophyseal glides, twice weekly for six weeks
Study NCT03362567 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mechanical Cervical Traction
Description: subjects in MCT received mechanical cervical traction, for 15 minutes each session twice in a week for six weeks
Study NCT03175302 — intervention group
Intervention type: BEHAVIORAL
Intervention: digital cognitive testing
Description: The digital testing is hypothesized to identify latent features for differentiating cognitively impaired presurgical patient subgroups
Study NCT04858958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furmonertinib 160mg
Description: randomized to 160mg QD
Study NCT04858958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furmonertinib 240mg
Description: randomized to 240mg QD
Study NCT01688466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: 0.5 mg/day with and/or without Dose Escalation and 0.5 mg/day- 2.0 mg/day by mouth (PO) QD(every day) of each 28 day cycle
Study NCT01104610 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Breas Vivo 40
Description: The Vivo 40 will be used either in CPAP mode, PSV mode without Target Volume or PSV mode with Target Volume
Study NCT00402181 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Siltuximab
Description: Siltuximab 6 mg/kg as intravenous infusion once every 2 weeks for 12 cycles and duration of each cycle is 28 days.
Study NCT00402181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 40 mg tablet orally on Day 1 to 4, 9 to 12 and 17 to 20 for maximum 4 cycles after that on Day 1 to 4 up to 12 cycles and duration of each cycle is 28 days.
Study NCT04552964 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Single arm
Description: Far Best Corrected Visual Acuity (BCVA) ; Intra-Ocular Pressure (IOP) assessment ; Fundus examination ; Automated visual field ; Slit lamp examination ; Pregnancy test ; Patient Satisfaction Questionnaire
Study NCT03607929 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: optimal
Description: Physiological Saline Solution
Study NCT00081224 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT00081224 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery
Study NCT02401659 — intervention group
Intervention type: DEVICE
Intervention: CareLinK
Study NCT01513720 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamotrigine
Description: Lamotrigine Tablets 200 mg
Study NCT01513720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Description: Lamotrigine Tablets 200 mg
Study NCT01513720 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamictal®
Description: Lamictal® 200 mg Tablets
Study NCT01513720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamictal®
Description: Lamictal® 200 mg Tablets
Study NCT01985529 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Study NCT03135054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quizartinib
Description: Quizartinib is an oral FLT3 receptor tyrosine kinase inhibitor
Study NCT03135054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omacetaxine Mepesuccinate Injection
Description: Omacetaxine Mepesuccinate is a pharmaceutical drug substance that is indicated for treatment of chronic myeloid leukemia (CML)
Study NCT01473433 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pericardial adipose pedicle (adiFLAP) transposition.
Description: Patients with a established transmural necrosis, candidates for revascularization of other myocardial areas, will be enrolled. The non-revascularizable area will be covered by the adiFLAP and the revascularizable area will be treated with the normal procedure. A non-revascularizable area will be considered whenever a transmural necrosis is detected by means of gadolinium contrast using MRI.
Study NCT01473433 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Patients with a established transmural necrosis, candidates for revascularization of other myocardial areas, will be enrolled. The non-revascularizable area will be left untouched and the revascularizable area will be treated normally (by-pass).
Study NCT00502970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 16 weeks Interferon Tiw with Ribavirin
Description: 16 weeks Interferon Tiw